Aurinia Pharmaceuticals's EBIT per Share for the
three
months ended in Mar. 2026 was $0.33.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $1.00.
During the past 12 months, the average EBIT per Share Growth Rate of Aurinia Pharmaceuticals was 173.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Aurinia Pharmaceuticals's EBIT per Share or its related term are showing as below:
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Aurinia Pharmaceuticals was 50.90% per year. The lowest was -152.00% per year. And the median was 4.00% per year.
AUPH's 3-Year EBIT Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 15.4 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
Aurinia Pharmaceuticals (NAS:AUPH) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Aurinia Pharmaceuticals EBIT per Share Related Terms
Aurinia Pharmaceuticals EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aurinia Pharmaceuticals (AUPH) has a EBIT per Share of $1.00 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Aurinia Pharmaceuticals and its competitors. According to the industry distribution chart, Aurinia Pharmaceuticals ranks #999999 out of 1172 companies in the Biotechnology industry.
Is Aurinia Pharmaceuticals' EBIT per Share too high?
Aurinia Pharmaceuticals' current EBIT per Share is $1.00. The Biotechnology industry median EBIT per Share is 15.40. Aurinia Pharmaceuticals' value of $1.00 is 93.5% below this industry median. Based on the distribution chart, Aurinia Pharmaceuticals ranks #999999 out of 1172 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Aurinia Pharmaceuticals has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aurinia Pharmaceuticals' EBIT per Share compare to KOD and ABCL?
According to the Biotechnology industry distribution chart, Aurinia Pharmaceuticals ranks #999999 out of 1172 companies for EBIT per Share. This places Aurinia Pharmaceuticals in the lower half of its industry. The industry median EBIT per Share is 15.40. Aurinia Pharmaceuticals' value of $1.00 is 93.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,172 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aurinia Pharmaceuticals's current EBIT per Share of $1.00 is 93.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Aurinia Pharmaceuticals and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aurinia Pharmaceuticals's current EBIT per Share is $1.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurinia Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Aurinia Pharmaceuticals (AUPH) is currently considered Modestly Overvalued. The stock's GF Value™ is $14.02, compared to a current price of $16.59 — trading 18.3% above its estimated fair value. The current EBIT per Share is $1.00 and 93.5% below the Biotechnology industry median of 15.40. Aurinia Pharmaceuticals' overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Aurinia Pharmaceuticals (AUPH), the current EBIT per Share is $1.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aurinia Pharmaceuticals (AUPH) Overvalued in 2026?
Based on GuruFocus' analysis, Aurinia Pharmaceuticals stock appears to be overvalued.
The current stock price of $16.59 is trading 18.3% above its estimated GF Value™ of $14.02.
GuruFocus considers Aurinia Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for AUPH:
EBIT per Share: $1.00
GF Value™: $14.02 vs. price of $16.59 (18.3% above fair value)
Industry Position: 93.5% below the Biotechnology median (#999999 of 1172)
No single metric tells the full story. See the AUPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
80GF Score
Get the complete analysis for AUPH
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AUPH has been successfully added to your 
